New 'Living Drug' trial targets Tough-to-Treat stomach and colon cancers
Disease control
Recruiting now
This study is testing a new personalized cell therapy called CHM-2101 for people with advanced stomach, colon, or neuroendocrine cancers that have come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to be…
Phase: PHASE1, PHASE2 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC